{"title":"Insulin Icodec (Awiqli)","authors":"Cadth","doi":"10.51731/cjht.2024.912","DOIUrl":null,"url":null,"abstract":"\nCADTH recommends that Awiqli be reimbursed by public drug plans for the once-weekly treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycemic control if certain conditions are met. \nAwiqli should only be covered to treat adults with T2DM whose glycated hemoglobin (hemoglobin A1C) is between 7.0% and 11.0% (inclusive). \nTo ensure cost-effectiveness, the total drug cost of Awiqli should not exceed the total drug cost of the least costly long-acting basal insulin analogue. \n","PeriodicalId":505661,"journal":{"name":"Canadian Journal of Health Technologies","volume":"6 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Health Technologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51731/cjht.2024.912","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
CADTH recommends that Awiqli be reimbursed by public drug plans for the once-weekly treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycemic control if certain conditions are met.
Awiqli should only be covered to treat adults with T2DM whose glycated hemoglobin (hemoglobin A1C) is between 7.0% and 11.0% (inclusive).
To ensure cost-effectiveness, the total drug cost of Awiqli should not exceed the total drug cost of the least costly long-acting basal insulin analogue.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
